Clinical Trial Update: A Study to Evaluate Immunity to Varicella Zoster Virus After Immunization With V212 Vaccine or Zostavax (V212-003) [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating immune response to Varicella Zoster Virus after immunization with V212 vaccine or Zostavax; results posted in 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Herpes Zoster

Drugs mentioned

• V212 vaccine
• Zostavax (Varicella zoster vaccine live)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Herpes Zoster | Phase 1 | Status: COMPLETED | Results posted: 2011-04-13